カテゴリ： GlobalData, アメリカ, 企業調査

Laboratory Corp of America Holdings (LH)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Laboratory Corp of America Holdings (LH) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8010891
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月21日
◆ページ数：155
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It focuses on the development and commercialization of a wide range of diagnostic technologies and testing services. The company offers clinical diagnostics laboratory services such as core testing, genomic and esoteric testing. Its services include general and specialty laboratory testing, ambulatory monitoring services, bone marrow and human leukocyte antigen (HLA) testing, clinical trials services, drug testing services, DNA identification services, forensic identity services, insurance health plan services, paternity testing services, patient services, personalized medicine and hospital services. It also offers drug development services through Covance. It offers its services to managed care organizations, physicians, hospitals, government agencies and biotechnology and pharmaceutical companies through a network of primary laboratories and patient service centers. The company has operations across the US, Columbia, Belgium, Puerto Rico, Japan, China, Singapore, the UK and three Canadian provinces. LabCorp is headquartered in Burlington, North Carolina, the US.

Laboratory Corp of America Holdings (LH) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Laboratory Corp of America Holdings, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Laboratory Corp of America Holdings, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Laboratory Corp of America Holdings, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Laboratory Corp of America Holdings, Medical Equipment, Deals By Market, 2011 to YTD 2017 11
Laboratory Corp of America Holdings, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Laboratory Corp of America Holdings, Medical Equipment, Deal Details 16
Asset Purchase 16
Sequenom Acquires Noninvasive Prenatal Testing Intellectual Property from Isis Innovation for USD14.5 Million 16
Pharma Tech Solutions Acquires Genstrip From Shasta Technologies 18
Sequenom Acquires Molecular Diagnostic Application Patents From Helicos BioSciences For US$1.3 Million 19
Gamma-Dynacare Medical Acquires Medical Labs Division Of Warnex 20
Venture Financing 21
OmniSeq Plans to Raise Funds through Series B Financing 21
Sera Prognostics Raises USD40 Million in Series C Financing 22
Seventh Sense Biosystems Raises USD10 Million in Series C Financing 23
Ativa Medical Raises USD15 Million in Series B Financing 25
Vivify Health Raises Funds in Series B Venture Financing 26
Seventh Sense Biosystems Raises USD16 Million in Series B Financing 27
Flatiron Health Raises US$130 Million In Series B Financing 29
Flatiron Health Raises US$8 Million In Series A Financing 30
Private Equity 32
Shore Capital Invests In ClearPath Diagnostics 32
Partnerships 33
Sequenom Enters into Licensing Agreement with Mayo Medical Labs 33
Sequenom Enters Into Licensing Agreement With Laboratoire Cerba For MaterniT21 PLUS 34
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 35
Sequella Enters Into Licensing Agreement With LabCorp For B-Smart Technology 36
LipoScience Enters Into Licensing Agreement With Cleveland Clinic 37
LabCorp Enters Into Licensing Agreement With OPKO Health For Alzheimer’s Diagnostic Technology 38
Sequenom Enters Into Licensing Agreement With LifeCodexx 39
MC10 Enters into Partnership with LabCorp 40
OmniSeq Enters into Distribution Agreement with Laboratory Corp of America 41
Sera Prognostics Enters into Agreement with LabCorp 42
Interpace Diagnostics Extends Agreement with LabCorp 43
Sequenom enters into an Agreement with University of California 44
Sysmex Enters into Co-Development Agreement with LabCorp 45
Cypher Genomics Enters into Agreement with Sequenom to Develop Next Generation Noninvasive Prenatal Tests 46
Gamma-Dynacare Medical Labs Enters Into Agreement With OSR Medical 47
Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments 48
Enzo Clinical Labs And Sequenom Enter Into Agreement To Market MaterniT21 Plus 49
Sequenom And CombiMatrix Enter Into Agreement To Market Chromosomal Microarray Analysis For Prenatal Testing 50
CombiMatrix Expands Co-Marketing Agreement With Pathology For Prenatal Tests 51
CombiMatrix Enters Into Co-Marketing Agreement With Pathology For Prenatal Tests 52
Mitomics Enters Into Co-Marketing Agreement With LabCorp For Prostate Core Mitomic Test 53
XDx Enters Into Agreement With LabCorp To Develop Lupus Flare Predictor Test 54
Emdeon Enters Into Strategic Alliance With LabCorp 55
Merger 56
instaCare Receives Merger Offer From A NASDAQ Traded Company 56
New England Biolabs Enters Into Licensing Agreement With Sequenom 57
Equity Offering 58
MC10 Raises Funds through Private Placement of Shares 58
LipoScience Completes IPO For US$52 Million 59
Sequenom Completes Public Offering Of Common Stock For US$62 Million 61
Debt Offering 63
LabCorp Raises USD600 Million in Public Offering of 3.6% Notes Due 2027 63
LabCorp Raises USD600 Million in Public Offering of 3.25% Notes Due 2024 65
LabCorp Raises USD500 Million in Public Offering of 2.625% Notes Due 2020 67
LabCorp Raises USD1 Billion in Public Offering of 3.6% Notes Due 2025 69
LabCorp Raises USD900 Million in Public Offering of 4.7% Notes Due 2045 71
LabCorp Raises USD500 Million in Public Offering of 3.2% Notes Due 2022 73
LabCorp Completes Public Offering Of Notes Due 2018 For US$400 Million 75
LabCorp Completes Public Offering Of Notes Due 2023 For US$300 Million 77
Sequenom Completes Private Placement Of Notes Due 2017 For US$130 Million 79
LabCorp Completes Public Offering Of Senior Notes Due 2017 For US$500 Million 80
LabCorp Completes Public Offering Of Senior Notes Due 2022 For US$500 Million 82
Asset Transactions 84
Sequenom Plans to Sell Clinical Genomic Lab in North Carolina 84
Marken Acquires European Kit Building Operation Facility From LabCorp 85
Acquisition 86
LabCorp Acquires Pathology Associates Medical Labs from Providence Health & Services and Catholic Health Initiatives 86
LabCorp Acquires ClearPath Diagnostics from Shore Capital Partners 88
LabCorp Acquires Sequenom 89
LabCorp Acquires Covance for USD6.1 Billion 91
LabCorp Acquires Bode Technology from SolutionPoint 93
LabCorp Acquires LipoScience for USD85.3 Million 94
Agena Bioscience Completes Acquisition of Sequenom Bioscience for USD31.8 Million 96
Gamma-Dynacare Medical Labs Acquires Controlling Interest In Impact Genetics 97
LabCorp Acquires Minority Stake In SynapDx For US$2 Million 98
LabCorp Completes Acquisition Of Medtox Scientific For US$241 Million 99
Bode Technology Group Acquires Provider Of DNA Analysis Testing Services, Chromosomal Labs 101
LabCorp Completes Acquisition Of Orchid Cellmark For US$85 Million 102
Pathology Holdings Acquires Central Coast Clinical Labs 105
Laboratory Corp of America Holdings – Key Competitors 106
Laboratory Corp of America Holdings – Key Employees 107
Laboratory Corp of America Holdings – Locations And Subsidiaries 108
Head Office 108
Other Locations & Subsidiaries 108
Recent Developments 113
Strategy And Business Planning 113
Jun 14, 2017: Covance Opens State-of-the-Art Laboratory for Companion Diagnostics 113
Apr 21, 2017: Covance to Expand Large-Molecule Development Capabilities in the UK 114
Financial Announcements 115
Oct 25, 2017: LabCorp Announces Record Third Quarter Results and Increases 2017 Guidance 115
Jul 26, 2017: LabCorp Announces Record Results in the Second Quarter of 2017 and Increases 2017 Guidance 117
Apr 25, 2017: Laboratory Corporation of America Holdings Announces 2017 First Quarter Results and Updates 2017 Guidance 120
Feb 16, 2017: Laboratory Corporation of America Holdings Announces Record 2016 Fourth Quarter and Full Year Results and Provides 2017 Guidance 122
Oct 26, 2016: Laboratory Corporation of America Holdings Announces 2016 Third Quarter Results and Updates 2016 Guidance 125
Jul 27, 2016: Laboratory Corporation of America Holdings Announces 2016 Second Quarter Results and Raises 2016 Guidance 128
Apr 25, 2016: Laboratory Corporation of America Holdings Announces 2016 First Quarter Results and Raises 2016 Guidance 130
Feb 18, 2016: Laboratory Corporation of America Holdings Announces 2015 Fourth Quarter and Full Year Results and Provides 2016 Guidance 132
Corporate Communications 135
Aug 24, 2017: LabCorp Names Nationally Recognized Health-Policy Expert Dr. Brian Caveney As Enterprise-Wide Chief Medical Officer 135
Jul 18, 2017: LabCorp’s William Hanlon Appointed to Governing Committee of the National Evaluation System for health Technology Coordinating Center 136
Mar 29, 2017: LabCorp Promotes Executive Gary Huff to CEO of LabCorp Diagnostics, One of the Company’s Two Primary Business Segments 137
Sep 20, 2016: LabCorp Names Veteran Biopharma Executive John Ratliff CEO of Covance Drug Development 138
Apr 11, 2016: LabCorp Hires Jonathan Zung as Group President of Clinical Development and Commercialization Services for Covance Drug Development 139
Jan 07, 2016: LabCorp Announces New Board Member 140
Legal and Regulatory 141
Jun 15, 2017: Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation 141
Oct 03, 2016: Oxford Immunotec Announces Favorable Decision from U.S. District Court of Massachusetts in Patent Infringement Litigation 142
Sep 01, 2016: Oxford Immunotec Announces Favorable Recommendation by the Magistrate Judge in Patent Infringement Litigation 143
Product News 144
Nov 16, 2017: Cority Enhances Clinical Testing Solution with LabCorp Interface 144
Sep 14, 2017: LabCorp Presents Nine Studies, Including Novel Research on Improving Genetic Counseling Quality, at the National Society of Genetic Counselors Annual Conference 145
Apr 28, 2017: LabCorp to Exclusively Offer the M3 Checklist, a Multi-Condition Mental Health Screening Tool 146
Jun 01, 2016: One Year After Launch, BRCA Share Open Data Initiative Reveals New Findings on BRCA Gene Mutations Linked to Hereditary Breast and Ovarian Cancer Risk 148
Jan 04, 2016: Proprietary LabCorp Clinical Decision Support Report Improves Adherence to Chronic Kidney Disease Treatment Guidelines 150
Other Significant Developments 151
Sep 25, 2017: LabCorp Objects to Proposed PAMA 2018 Medicare Payment Rates for Clinical Laboratory Tests; Calls for Delay in Implementation to Avoid Significant Harm to Medicare Beneficiaries 151
Jul 11, 2017: LabCorp and Novant Health Extend Laboratory Services Agreement 152
Jun 28, 2017: Walgreens and LabCorp Collaborate to Bring Patient Service Centers for Laboratory Testing to Select Walgreens Stores 153
Mar 14, 2016: Covance Announces Mobile Health Solutions to Support Use of Mobile Technology in Clinical Trials 154
Appendix 155
Methodology 155
About GlobalData 155
Contact Us 155
Disclaimer 155

List of Tables
Laboratory Corp of America Holdings, Medical Equipment, Key Facts, 2016 2
Laboratory Corp of America Holdings, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Laboratory Corp of America Holdings, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Laboratory Corp of America Holdings, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Laboratory Corp of America Holdings, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Laboratory Corp of America Holdings, Deals By Market, 2011 to YTD 2017 11
Laboratory Corp of America Holdings, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Sequenom Acquires Noninvasive Prenatal Testing Intellectual Property from Isis Innovation for USD14.5 Million 16
Pharma Tech Solutions Acquires Genstrip From Shasta Technologies 18
Sequenom Acquires Molecular Diagnostic Application Patents From Helicos BioSciences For US$1.3 Million 19
Gamma-Dynacare Medical Acquires Medical Labs Division Of Warnex 20
OmniSeq Plans to Raise Funds through Series B Financing 21
Sera Prognostics Raises USD40 Million in Series C Financing 22
Seventh Sense Biosystems Raises USD10 Million in Series C Financing 23
Ativa Medical Raises USD15 Million in Series B Financing 25
Vivify Health Raises Funds in Series B Venture Financing 26
Seventh Sense Biosystems Raises USD16 Million in Series B Financing 27
Flatiron Health Raises US$130 Million In Series B Financing 29
Flatiron Health Raises US$8 Million In Series A Financing 30
Shore Capital Invests In ClearPath Diagnostics 32
Sequenom Enters into Licensing Agreement with Mayo Medical Labs 33
Sequenom Enters Into Licensing Agreement With Laboratoire Cerba For MaterniT21 PLUS 34
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 35
Sequella Enters Into Licensing Agreement With LabCorp For B-Smart Technology 36
LipoScience Enters Into Licensing Agreement With Cleveland Clinic 37
LabCorp Enters Into Licensing Agreement With OPKO Health For Alzheimer's Diagnostic Technology 38
Sequenom Enters Into Licensing Agreement With LifeCodexx 39
MC10 Enters into Partnership with LabCorp 40
OmniSeq Enters into Distribution Agreement with Laboratory Corp of America 41
Sera Prognostics Enters into Agreement with LabCorp 42
Interpace Diagnostics Extends Agreement with LabCorp 43
Sequenom enters into an Agreement with University of California 44
Sysmex Enters into Co-Development Agreement with LabCorp 45
Cypher Genomics Enters into Agreement with Sequenom to Develop Next Generation Noninvasive Prenatal Tests 46
Gamma-Dynacare Medical Labs Enters Into Agreement With OSR Medical 47
Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments 48
Enzo Clinical Labs And Sequenom Enter Into Agreement To Market MaterniT21 Plus 49
Sequenom And CombiMatrix Enter Into Agreement To Market Chromosomal Microarray Analysis For Prenatal Testing 50
CombiMatrix Expands Co-Marketing Agreement With Pathology For Prenatal Tests 51
CombiMatrix Enters Into Co-Marketing Agreement With Pathology For Prenatal Tests 52
Mitomics Enters Into Co-Marketing Agreement With LabCorp For Prostate Core Mitomic Test 53
XDx Enters Into Agreement With LabCorp To Develop Lupus Flare Predictor Test 54
Emdeon Enters Into Strategic Alliance With LabCorp 55
instaCare Receives Merger Offer From A NASDAQ Traded Company 56
New England Biolabs Enters Into Licensing Agreement With Sequenom 57
MC10 Raises Funds through Private Placement of Shares 58
LipoScience Completes IPO For US$52 Million 59
Sequenom Completes Public Offering Of Common Stock For US$62 Million 61
LabCorp Raises USD600 Million in Public Offering of 3.6% Notes Due 2027 63
LabCorp Raises USD600 Million in Public Offering of 3.25% Notes Due 2024 65
LabCorp Raises USD500 Million in Public Offering of 2.625% Notes Due 2020 67
LabCorp Raises USD1 Billion in Public Offering of 3.6% Notes Due 2025 69
LabCorp Raises USD900 Million in Public Offering of 4.7% Notes Due 2045 71
LabCorp Raises USD500 Million in Public Offering of 3.2% Notes Due 2022 73
LabCorp Completes Public Offering Of Notes Due 2018 For US$400 Million 75
LabCorp Completes Public Offering Of Notes Due 2023 For US$300 Million 77
Sequenom Completes Private Placement Of Notes Due 2017 For US$130 Million 79
LabCorp Completes Public Offering Of Senior Notes Due 2017 For US$500 Million 80
LabCorp Completes Public Offering Of Senior Notes Due 2022 For US$500 Million 82
Sequenom Plans to Sell Clinical Genomic Lab in North Carolina 84
Marken Acquires European Kit Building Operation Facility From LabCorp 85
LabCorp Acquires Pathology Associates Medical Labs from Providence Health & Services and Catholic Health Initiatives 86
LabCorp Acquires ClearPath Diagnostics from Shore Capital Partners 88
LabCorp Acquires Sequenom 89
LabCorp Acquires Covance for USD6.1 Billion 91
LabCorp Acquires Bode Technology from SolutionPoint 93
LabCorp Acquires LipoScience for USD85.3 Million 94
Agena Bioscience Completes Acquisition of Sequenom Bioscience for USD31.8 Million 96
Gamma-Dynacare Medical Labs Acquires Controlling Interest In Impact Genetics 97
LabCorp Acquires Minority Stake In SynapDx For US$2 Million 98
LabCorp Completes Acquisition Of Medtox Scientific For US$241 Million 99
Bode Technology Group Acquires Provider Of DNA Analysis Testing Services, Chromosomal Labs 101
LabCorp Completes Acquisition Of Orchid Cellmark For US$85 Million 102
Pathology Holdings Acquires Central Coast Clinical Labs 105
Laboratory Corp of America Holdings, Key Competitors 106
Laboratory Corp of America Holdings, Key Employees 107
Laboratory Corp of America Holdings, Other Locations 108
Laboratory Corp of America Holdings, Subsidiaries 109

★海外企業調査レポート[Laboratory Corp of America Holdings (LH)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Societe Generale S.A.：企業の戦略・SWOT・財務情報
    Societe Generale S.A. - Strategy, SWOT and Corporate Finance Report Summary Societe Generale S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • MorphoSys AG (MOR)：企業の財務・戦略的SWOT分析
    Summary MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, and research applications. The company’s pipeline products include MOR208, MOR103, MOR202, MAA868, VAY736, MOR106, and MOR107. Its drugs are used for the treatment of various types of cancers, psoriasis, rheuma …
  • First Horizon National Corporation：企業の戦略・SWOT・財務情報
    First Horizon National Corporation - Strategy, SWOT and Corporate Finance Report Summary First Horizon National Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Energiekontor AG (EKT)：企業の財務・戦略的SWOT分析
    Summary Energiekontor AG (Energiekontor) is a renewable energy company that develops and operates offshore wind farms. The company operates in the field of project development and sales, power generation in group-owned wind farms, and operation development services. Its services include construction …
  • Cleanaway Waste Management Ltd (CWY)：企業の財務・戦略的SWOT分析
    Cleanaway Waste Management Ltd (CWY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • The Northwestern Mutual Life Insurance Company：企業の戦略・SWOT・財務情報
    The Northwestern Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary The Northwestern Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Orexigen Therapeutics Inc (OREX)-製薬・医療分野：企業M&A・提携分析
    Summary Orexigen Therapeutics Inc (Orexigen) is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. Its lead product, Contrave (naltrexone HCl / bupropion HCl prolonged release) is FDA approved as an adjunct to a reduced-calorie diet and increased …
  • QHR Corporation：医療機器：M&Aディール及び事業提携情報
    Summary QHR Corporation (QHR), a subsidiary of Shoppers Drug Mart Inc. (SDMI), formerly known as QHR Technologies Inc., is a healthcare technology provider. It offers electronic medical records (EMR) for healthcare professionals including family physicians, medical specialists, and surgeons. The com …
  • Vistra Energy Corp (VST)：電力：M&Aディール及び事業提携情報
    Summary Vistra Energy Corp (Vistra Energy) is an investment holding company engaged in operation of integrated power business. The company through its subsidiaries is involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, and retail sales of e …
  • Rockwell Automation, Inc.：企業の戦略・SWOT・財務分析
    Rockwell Automation, Inc. - Strategy, SWOT and Corporate Finance Report Summary Rockwell Automation, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Ormat Technologies Inc (ORA)：電力：M&Aディール及び事業提携情報
    Summary Ormat Technologies, Inc. (Ormat), is a vertically integrated company that focuses on the geothermal and recovered energy generation. The company designs, develops, builds, owns, and operates the geothermal and recovered energy generation (REG) power plants. Ormat also supplies geothermal and …
  • Symbiomix Therapeutics LLC-製薬・医療分野：企業M&A・提携分析
    Summary Symbiomix Therapeutics LLC (Symbiomix) is a drug development company that offers development and commercialization of novel medicines. The company offers SYM-1219, for the treatment of several serious infections in women including bacterial vaginosis. Its SYM-1219 contains secnidazole, nitro …
  • The Toronto-Dominion Bank：企業の戦略・SWOT・財務分析
    The Toronto-Dominion Bank - Strategy, SWOT and Corporate Finance Report Summary The Toronto-Dominion Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Volkswagen AG (VOW3)：企業の財務・戦略的SWOT分析
    Volkswagen AG (VOW3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • GammaDelta Therapeutics Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary GammaDelta Therapeutics Ltd (GammaDelta Therapeutics) is an immunotherapy company that develops immunotherapies for cancer and other immune related diseases. The company conducts research and development focused on exploiting tissue resident gamma delta T cells, which are conserved populatio …
  • RATP Group：企業の戦略・SWOT・財務情報
    RATP Group - Strategy, SWOT and Corporate Finance Report Summary RATP Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Plug Power Inc (PLUG)：企業の財務・戦略的SWOT分析
    Summary Plug Power Inc (Plug Power) is an alternative energy company that designs and develops fuel cell structures. The company’s products comprise gendrive, genkey, material handling products, gensure, genfuel and genfuel for stationary markets products. Its material handling products comprise out …
  • Hokkaido Electric Power Co., Inc.：企業の戦略・SWOT・財務分析
    Hokkaido Electric Power Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Hokkaido Electric Power Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Spark Therapeutics Inc (ONCE)：製薬・医療：M&Aディール及び事業提携情報
    Summary Spark Therapeutics Inc (Spark) is a clinical-stage gene therapy company which provides gene therapies for inherited retinal diseases (IRDs), neurodegenerative diseases, as well as liver diseases. Its pipeline products include SPK-RPE65, SPK-CHM, rhonova, LHON, SPK-FIX, SPK-FVIII and SPK-TPP1 …
  • Titan Medical Inc (TMD)：医療機器：M&Aディール及び事業提携情報
    Summary Titan Medical Inc (Titan) is a development stage company that designs and develops a robotic surgical system for application in minimally invasive surgery (MIS). The company's lead product candidate, single port robotic (SPORT) surgical system is a single-incision robotic surgical system. It …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆